Survival rates for women with stage I-II ovarian clear cell carcinoma (OCCC) were similar after 3 or 6 cycles of platinum-based chemotherapy, a recent study found, and patients with early stage I and II OCCC may be candidates for a 3-cycle treatment approach. The cohort included 210 patients (median age 53 years) with stage I-II OCCC treated at 5 institutions from January 1994 through December 2011 and identified and divided into 2 groups: those who received 3 vs 6 cycles of adjuvant chemotherapy. Researchers found:

• All patients received adjuvant chemotherapy with 90% receiving carboplatin and paclitaxel.
• 38 (18.1%) patients received 3 cycles, and 172 (81.9%) patients received 6 cycles of adjuvant treatment.
• Recurrence rate was comparable between groups (18.4% vs 27.3% for 3 vs 6 cycles).
• No impact of 3 vs 6 cycles of chemotherapy on progression-free survival was observed.
• No benefit was found in more chemotherapy in stratified analysis by stage nor on multivariate analysis adjusting for the impact of stage.